Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCFinancial_Report.xls
10-Q - FORM 10-Q - HI TECH PHARMACAL CO INCd399017d10q.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR7.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR6.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR8.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR2.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR5.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR3.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR4.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR1.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR9.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR49.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR23.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR40.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR38.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR27.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR34.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR50.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR28.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR21.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR17.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR16.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR48.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR55.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR37.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR56.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR31.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR29.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR15.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR32.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR13.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR54.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR10.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR43.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR18.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR53.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR12.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR35.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR36.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR19.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR42.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR24.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR45.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR25.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR46.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR20.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR41.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR22.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR11.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR39.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR47.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR26.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR44.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR30.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR14.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR52.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR33.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR51.htm
EX-32 - EX-32 - HI TECH PHARMACAL CO INCd399017dex32.htm
EX-31.1 - EX-31.1 - HI TECH PHARMACAL CO INCd399017dex311.htm

Exhibit 31.2

HI-TECH PHARMACAL CO., INC.

CERTIFICATION PURSUANT TO RULE 13A-14 OR 15D-14 OF THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, WILLIAM PETERS, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of Hi-Tech Pharmacal Co., Inc.

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c. evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d. disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of the annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

 

  a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: December 7, 2012

 

By:  

/s/ William Peters

  William Peters
  Chief Financial Officer